RxDoctor Payments DataLook up a doctor →

Marin Xavier, MD

Medical Oncology · San Diego, CANPI 1437211372

Payments from drug & device makers

$1,943,312in general payments, 2019–2025

Across 1,767 payments — averaging $1099.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$466K
  • Incyte Corporation$366K
  • AbbVie$320K
  • AstraZeneca$128K
  • Lilly USA, LLC$97K
  • Bristol Myers Squibb$87K
  • plus $478K from 54 others
$94in research payments, 2019–2025

Across 3 payments — averaging $31.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$94

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly18$466,279
Incyte Corporation159$366,321
AbbVie158$319,665
AstraZeneca(2 entities)171$127,784
Lilly USA, LLC78$96,860
Bristol Myers Squibb111$87,035
Beigene USA, Inc.69$78,795
E.r. Squibb & Sons, L.L.C.56$70,697
Genentech, Inc.4$63,836
Takeda Pharmaceuticals U.S.A., Inc.25$24,082
Gilead(2 entities)42$23,468
Seagen Inc.47$22,553
Genmab U.S., Inc.24$16,983
Genentech USA, Inc.69$16,915
ADC Therapeutics America, Inc.15$16,748
Acrotech Biopharma Inc.8$13,059
Astellas Pharma US Inc26$12,515
GSK37$12,367
Epizyme, Inc.14$11,766
Blueprint Medicines Corporation16$9,369
Beone Medicines USA, Inc.6$9,252
Aurobindo Pharma USA, Inc.7$8,035
Geron Corporation8$6,584
Astrazeneca UK Limited9$6,377
Beigene, Ltd.3$6,000
Pharmacyclics LLC, An Abbvie Company32$5,925
Ipsen Biopharmaceuticals, Inc10$4,583
Johnson & Johnson(2 entities)49$4,338
Beone Medicines Ltd.2$4,050
Stemline Therapeutics Inc.9$3,976
Morphosys, US Inc.4$3,583
Sobi, Inc13$3,475
Taiho Oncology, Inc.6$3,347
Verastem, Inc.1$1,680
Agios Pharmaceuticals, Inc.9$1,663
CTI Biopharma Corp.2$1,620
Janssen Scientific Affairs, LLC1$1,515
Merck69$1,223
Novartis41$900
Amgen38$891
Teva Pharmaceuticals USA, Inc.35$699
Pfizer30$639
Eisai Inc.19$464
TG Therapeutics, Inc.1$450
Karyopharm Therapeutics Inc.18$419
Sanofi13$295
Clovis Oncology, Inc.17$290
Pharmaessentia USA Corporation9$280
Exelixis Inc.11$260
Array Biopharma Inc11$249
Foundation Medicine, Inc.13$242
Regeneron Healthcare Solutions, Inc.8$233
Daiichi Sankyo Inc.11$229
Rigel Pharmaceuticals, Inc.8$209
Boehringer Ingelheim9$182
Puma Biotechnology, Inc.7$169
Tersera Therapeutics LLC6$151
Stryker1$150
Bayer6$125
Coherus Oncology, Inc.5$114

How this compares

$1,943,312 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$363,440
Medicare patients
529
Services billed
6,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →